annual EBITDA:
-$178.85M+$79.39M(+30.74%)Summary
- As of today (May 29, 2025), ALNY annual EBITDA is -$178.85 million, with the most recent change of +$79.39 million (+30.74%) on December 31, 2024.
- During the last 3 years, ALNY annual EBITDA has risen by +$440.58 million (+71.13%).
- ALNY annual EBITDA is now -4172.50% below its all-time high of -$4.19 million, reached on December 31, 2002.
Performance
ALNY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$11.46M+$166.44M(+107.39%)Summary
- As of today (May 29, 2025), ALNY quarterly EBITDA is $11.46 million, with the most recent change of +$166.44 million (+107.39%) on March 31, 2025.
- Over the past year, ALNY quarterly EBITDA has increased by +$26.27 million (+177.31%).
- ALNY quarterly EBITDA is now -94.42% below its all-time high of $205.17 million, reached on September 30, 2023.
Performance
ALNY quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$132.03M+$26.27M(+16.60%)Summary
- As of today (May 29, 2025), ALNY TTM EBITDA is -$132.03 million, with the most recent change of +$26.27 million (+16.60%) on March 31, 2025.
- Over the past year, ALNY TTM EBITDA has increased by +$4.70 million (+3.44%).
- ALNY TTM EBITDA is now -192.49% below its all-time high of $142.75 million, reached on June 30, 2024.
Performance
ALNY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ALNY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.7% | +177.3% | +3.4% |
| 3 y3 years | +71.1% | +106.5% | +79.5% |
| 5 y5 years | +78.5% | +107.0% | +84.1% |
ALNY EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +80.7% | -94.4% | +103.3% | -192.5% | +85.9% |
| 5 y | 5-year | at high | +80.7% | -94.4% | +103.3% | -192.5% | +85.9% |
| alltime | all time | -4172.5% | +80.7% | -94.4% | +103.3% | -192.5% | +85.9% |
ALNY EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $11.46M(-107.4%) | -$132.03M(-16.6%) |
| Dec 2024 | -$178.85M(-30.7%) | -$154.99M(+228.0%) | -$158.30M(+44.4%) |
| Sep 2024 | - | -$47.25M(-180.4%) | -$109.66M(-176.8%) |
| Jun 2024 | - | $58.75M(-496.5%) | $142.75M(-204.4%) |
| Mar 2024 | - | -$14.82M(-86.1%) | -$136.73M(-42.8%) |
| Dec 2023 | -$258.24M(-72.1%) | -$106.35M(-151.8%) | -$239.24M(-22.8%) |
| Sep 2023 | - | $205.17M(-193.0%) | -$310.00M(-63.9%) |
| Jun 2023 | - | -$220.73M(+88.1%) | -$859.37M(+1.0%) |
| Mar 2023 | - | -$117.33M(-33.8%) | -$850.47M(-6.6%) |
| Dec 2022 | -$926.56M(+49.6%) | -$177.11M(-48.5%) | -$910.36M(-2.7%) |
| Sep 2022 | - | -$344.21M(+62.5%) | -$935.29M(+27.8%) |
| Jun 2022 | - | -$211.83M(+19.5%) | -$731.82M(+13.9%) |
| Mar 2022 | - | -$177.22M(-12.3%) | -$642.49M(+3.7%) |
| Dec 2021 | -$619.43M(-11.1%) | -$202.03M(+43.5%) | -$619.43M(+1.3%) |
| Sep 2021 | - | -$140.74M(+14.9%) | -$611.60M(-9.5%) |
| Jun 2021 | - | -$122.49M(-20.5%) | -$675.80M(-1.5%) |
| Mar 2021 | - | -$154.16M(-20.6%) | -$686.19M(-1.5%) |
| Dec 2020 | -$696.67M(-16.2%) | -$194.20M(-5.2%) | -$696.67M(-8.8%) |
| Sep 2020 | - | -$204.95M(+54.2%) | -$764.29M(+1.2%) |
| Jun 2020 | - | -$132.88M(-19.3%) | -$754.94M(-8.9%) |
| Mar 2020 | - | -$164.64M(-37.1%) | -$828.40M(-1.2%) |
| Dec 2019 | -$830.88M(+11.5%) | -$261.82M(+33.9%) | -$838.45M(+14.3%) |
| Sep 2019 | - | -$195.60M(-5.2%) | -$733.56M(-7.4%) |
| Jun 2019 | - | -$206.34M(+18.1%) | -$792.12M(+2.1%) |
| Mar 2019 | - | -$174.69M(+11.3%) | -$775.89M(+4.1%) |
| Dec 2018 | -$745.43M(+52.7%) | -$156.93M(-38.3%) | -$745.43M(+1.6%) |
| Sep 2018 | - | -$254.15M(+33.7%) | -$733.55M(+21.9%) |
| Jun 2018 | - | -$190.12M(+31.8%) | -$601.61M(+13.7%) |
| Mar 2018 | - | -$144.23M(-0.6%) | -$528.91M(+8.3%) |
| Dec 2017 | -$488.19M(+19.2%) | -$145.06M(+18.7%) | -$488.19M(+7.2%) |
| Sep 2017 | - | -$122.21M(+4.1%) | -$455.55M(+4.4%) |
| Jun 2017 | - | -$117.41M(+13.4%) | -$436.51M(+7.1%) |
| Mar 2017 | - | -$103.51M(-7.9%) | -$407.54M(-0.5%) |
| Dec 2016 | -$409.46M(+47.8%) | -$112.42M(+9.0%) | -$409.46M(+6.5%) |
| Sep 2016 | - | -$103.18M(+16.7%) | -$384.49M(+8.5%) |
| Jun 2016 | - | -$88.44M(-16.1%) | -$354.37M(+6.1%) |
| Mar 2016 | - | -$105.43M(+20.6%) | -$333.85M(+20.5%) |
| Dec 2015 | -$276.96M(+60.8%) | -$87.44M(+19.7%) | -$276.96M(+19.4%) |
| Sep 2015 | - | -$73.06M(+7.6%) | -$231.89M(+15.4%) |
| Jun 2015 | - | -$67.92M(+40.0%) | -$200.91M(+12.2%) |
| Mar 2015 | - | -$48.53M(+14.5%) | -$179.01M(+3.9%) |
| Dec 2014 | -$172.29M(+108.3%) | -$42.37M(+0.7%) | -$172.29M(+9.8%) |
| Sep 2014 | - | -$42.08M(-8.6%) | -$156.88M(+8.7%) |
| Jun 2014 | - | -$46.03M(+10.1%) | -$144.27M(+23.5%) |
| Mar 2014 | - | -$41.81M(+55.0%) | -$116.84M(+41.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$82.71M(+51.7%) | -$26.96M(-8.5%) | -$82.71M(+7.3%) |
| Sep 2013 | - | -$29.47M(+58.4%) | -$77.08M(+21.4%) |
| Jun 2013 | - | -$18.60M(+142.3%) | -$63.47M(+16.8%) |
| Mar 2013 | - | -$7.68M(-64.0%) | -$54.33M(-0.4%) |
| Dec 2012 | -$54.53M(+9.7%) | -$21.33M(+34.5%) | -$54.53M(+19.7%) |
| Sep 2012 | - | -$15.86M(+67.6%) | -$45.55M(+11.5%) |
| Jun 2012 | - | -$9.46M(+20.1%) | -$40.87M(-5.5%) |
| Mar 2012 | - | -$7.88M(-36.2%) | -$43.23M(-13.0%) |
| Dec 2011 | -$49.69M(+28.1%) | -$12.35M(+10.5%) | -$49.69M(+3.2%) |
| Sep 2011 | - | -$11.18M(-5.5%) | -$48.13M(+8.4%) |
| Jun 2011 | - | -$11.83M(-17.5%) | -$44.42M(+3.3%) |
| Mar 2011 | - | -$14.34M(+32.9%) | -$42.99M(+10.8%) |
| Dec 2010 | -$38.80M(-5.4%) | -$10.79M(+44.6%) | -$38.80M(+14.7%) |
| Sep 2010 | - | -$7.46M(-28.3%) | -$33.84M(-3.1%) |
| Jun 2010 | - | -$10.40M(+2.5%) | -$34.92M(-22.4%) |
| Mar 2010 | - | -$10.14M(+74.0%) | -$44.98M(+9.7%) |
| Dec 2009 | -$41.02M(+116.6%) | -$5.83M(-31.7%) | -$41.02M(+7.9%) |
| Sep 2009 | - | -$8.54M(-58.3%) | -$38.02M(+22.3%) |
| Jun 2009 | - | -$20.47M(+231.3%) | -$31.09M(+40.6%) |
| Mar 2009 | - | -$6.18M(+117.7%) | -$22.10M(+16.8%) |
| Dec 2008 | -$18.93M(-74.8%) | -$2.84M(+77.0%) | -$18.93M(+368.0%) |
| Sep 2008 | - | -$1.60M(-86.0%) | -$4.04M(-92.3%) |
| Jun 2008 | - | -$11.48M(+282.1%) | -$52.73M(-4.6%) |
| Mar 2008 | - | -$3.01M(-124.9%) | -$55.26M(-26.4%) |
| Dec 2007 | -$75.06M(+110.3%) | $12.05M(-124.0%) | -$75.06M(-21.8%) |
| Sep 2007 | - | -$50.29M(+258.8%) | -$96.01M(+83.0%) |
| Jun 2007 | - | -$14.02M(-38.5%) | -$52.47M(+6.1%) |
| Mar 2007 | - | -$22.80M(+156.1%) | -$49.48M(+38.6%) |
| Dec 2006 | -$35.69M(-11.6%) | -$8.90M(+31.9%) | -$35.69M(-12.8%) |
| Sep 2006 | - | -$6.75M(-38.7%) | -$40.95M(-7.2%) |
| Jun 2006 | - | -$11.02M(+22.3%) | -$44.12M(+1.8%) |
| Mar 2006 | - | -$9.01M(-36.4%) | -$43.35M(+7.4%) |
| Dec 2005 | -$40.35M(+35.3%) | -$14.16M(+42.6%) | -$40.35M(+30.3%) |
| Sep 2005 | - | -$9.93M(-3.1%) | -$30.97M(+15.8%) |
| Jun 2005 | - | -$10.25M(+70.7%) | -$26.74M(+16.2%) |
| Mar 2005 | - | -$6.01M(+25.6%) | -$23.00M(-22.9%) |
| Dec 2004 | -$29.82M(+52.1%) | -$4.78M(-16.1%) | -$29.82M(-34.6%) |
| Sep 2004 | - | -$5.70M(-12.6%) | -$45.62M(+14.4%) |
| Jun 2004 | - | -$6.52M(-49.1%) | -$39.88M(+13.5%) |
| Mar 2004 | - | -$12.82M(-37.7%) | -$35.14M(+49.0%) |
| Dec 2003 | -$19.61M(+368.5%) | -$20.58M(<-9900.0%) | -$23.59M(+684.6%) |
| Sep 2003 | - | $44.00K(-102.5%) | -$3.01M(-1.4%) |
| Jun 2003 | - | -$1.78M(+40.9%) | -$3.05M(+140.9%) |
| Mar 2003 | - | -$1.27M | -$1.27M |
| Dec 2002 | -$4.19M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual EBITDA year-on-year change?
- What is Alnylam Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Alnylam Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM EBITDA year-on-year change?
What is Alnylam Pharmaceuticals annual EBITDA?
The current annual EBITDA of ALNY is -$178.85M
What is the all time high annual EBITDA for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual EBITDA is -$4.19M
What is Alnylam Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ALNY annual EBITDA has changed by +$79.39M (+30.74%)
What is Alnylam Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of ALNY is $11.46M
What is the all time high quarterly EBITDA for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly EBITDA is $205.17M
What is Alnylam Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ALNY quarterly EBITDA has changed by +$26.27M (+177.31%)
What is Alnylam Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of ALNY is -$132.03M
What is the all time high TTM EBITDA for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM EBITDA is $142.75M
What is Alnylam Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ALNY TTM EBITDA has changed by +$4.70M (+3.44%)